The following data will be presented: The Impact of Treatment Gaps on Effectiveness of Transcranial Magnetic Stimulation in MDD Presented by: Sonder Behavioral Health & Wellness, Minnetonka, Minnesota Overview: This study will showcase feasibility, safety, and efficacy results using NeuroStar with a pragmatic accelerated TMS protocol without the need for neuroimaging. Presentation Date: June 14th at 4:00 PM BST Presenter: Dr. Kenneth Pages, Medical Director of TMS of South Tampa Overview: Dr. Pages will con ...

"We are thrilled to present this meaningful evidence at the Clinical TMS Society Annual Meeting and engage with TMS providers and researchers about recent advancements in our field," said Cory Anderson, Senior Vice President of Research & Development and Clinical Affairs. "Our extensive data and strong clinical presence establish NeuroStar as the leading TMS device, treating the highest number of patients and supporting providers in delivering exceptional patient care in clinical settings." When to Hold and ...

MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Thursday, June 6, 2024. The Company is scheduled to present at 10:00am Central Time the same day via webcast. Neuronetics, Inc. believes that ment ...

Neuronetics, Inc. (NASDAQ:STIM) Q1 2024 Results Conference Call May 7, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President, Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Adam Maeder - Piper & Sandler Margaret Kaczor - William and Blair Danny Stauder - Citizens JMP Operator Thank you for standing by. Welcome to the Neuronetics First Quarter 2024 Conference Call. At this time all participants are in a listen-only mod ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) Delaware 33-10 ...

Exhibit 99.1 Neuronetics Reports Record First Quarter 2024 Financial and Operating Results MALVERN, PA., May 7, 2024 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 Highlights ● First quarter 20 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation or or ...

Neuronetics, Inc. (NASDAQ:STIM) Q4 2023 Earnings Conference Call March 5, 2024 8:30 AM ET Company Participants Keith Sullivan - President, Chief Executive Officer Steve Furlong - Chief Financial Officer Mark Klausner - Investor Relations Conference Call Participants Adam Maeder - Piper Margaret Kaczor - William Blair William Plovanic - Canaccord Danny Stauder - Citizens JMP Operator Ladies and gentlemen, thank you for standing by. Welcome to the Neuronetics Report Fourth Quarter 2023 Financial and Operating ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporat ...

Neuronetics, Inc. (NASDAQ:STIM) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and CEO Steve Furlong - CFO Conference Call Participants Margaret Kaczor - William Blair Adam Maeder - Piper Sandler Daniel Stauder - JMP Securities Operator Good day, and thank you for standing by. Welcome to the Neuronetics Third Quarter 2023 Conference Call. [Operator Instructions] Please be advised that today's conference call is being ...